Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.
Revolution Medicines, a US-based cancer treatment developer exploiting research from multiple universities, has filed for a $100m initial public offering on the Nasdaq Global Market.
Terms for the proposed offering have not yet been set.
Founded in 2014, Revolution Medicines is developing small molecule drugs for a range of cancers, with a focus on indications that currently lack a treatment or that where existing therapies are not able to fully inhibit all factors contributing to cancer growth.
The company’s lead asset, RMC-4630, targets a cell-growth modulating protein known as SHP2 with the aim of treating multiple cancer indications. The candidate is being developed in collaboration with pharmaceutical firm Sanofi and is currently undergoing phase 1/2 trials.
Revolution was established by biotech company builder Third Rock Ventures and co-founded by Martin Burke from University of Illinois at Urbana-Champaign, Michael Fischbach from Stanford University and Kevan Shokat from…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
